Abstract:Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type that urgently requires effective therapeutic strategies. Andrographolide, a labdane diterpenoid compound abundant in Andrographis paniculata, has anticancer effects against various cancer types, but its anticancer activity and mechanism against PDAC remain largely uncharacterized. Purpose: This study explores novel drug target(s) and underlying molecular mechanism of andrographolide against PDAC. Study design and methods: The malignant phenotypes of PDAC cells, PANC-1 and MIA PaCa-2 cells, were measured using MTT, clonogenic assays, and Transwell migration assays. A PDAC xenograft animal model was used to evaluate tumor growth in vivo. Western blot, immunofluorescence and immunohistochemistry were used for measuring protein expression. The TCGA database was analyzed to evaluate promoter methylation status, gene expression, and their relationship with patient survival rates. RT-qPCR was used for detecting mRNA expression. Reporter assays were used for detecting signal transduction pathways. Promoter DNA methylation was determined by sodium bisulfite treatment and methylation-specific PCR (MSP). The biological function and role of specific genes involved in drug effects were measured through gene overexpression. Results: Andrographolide treatment suppressed the proliferation and migration of PDAC cells and impaired tumor growth in vivo. Furthermore, andrographolide induced the mRNA and protein expression of zinc finger protein 382 (ZNF382) in PDAC cells. Overexpression of ZNF382 inhibited malignant phenotypes and cancer-associated signaling pathways (AP-1, NF-κB and β-catenin) and oncogenes (ZEB-1, STAT-3, STAT-5, and HIF-1α). Overexpression of ZNF382 delayed growth of PANC-1 cells in vivo. ZNF382 mRNA and protein expression was lower in tumor tissues than in adjacent normal tissues of pancreatic cancer patients. Analysis of the TCGA database found the ZNF382 promoter is hypermethylated in primary pancreatic tumors which correlates with its low expression. Furthermore, andrographolide inhibited the expression of DNA methyltransferase 3 beta (DNMT3B) and increased the demethylation of the ZNF382 promoter in PDAC cells. Overexpression of DNMT3B attenuated the andrographolide-suppressed proliferation and migration of PDAC cells. Conclusion: Our finding revealed that ZNF382 acts as a tumor suppressor gene in pancreatic cancer and andrographolide restores ZNF382 expression to suppress pancreatic cancer, providing a novel molecular target and a promising therapeutic approach for treating pancreatic cancer.

Andrographolide Inhibits Tumor Angiogenesis Via Blocking VEGFA/VEGFR2-MAPKs Signaling Cascade

Andrographolide Inhibits Breast Cancer Through Suppressing COX-2 Expression and Angiogenesis Via Inactivation of P300 Signaling and VEGF Pathway.

A Novel Semi-Synthetic Andrographolide Analogue A5 Inhibits Tumor Angiogenesis Via Blocking the Vegfr2-P38/ Erk1/2 Signal Pathway

Acetyl-11-Keto-Beta-Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis

Andrographolide Protects against HG-Induced Inflammation, Apoptosis, Migration, and Impairment of Angiogenesis via PI3K/AKT-eNOS Signalling in HUVECs

Andrographolide inhibits the adhesion of gastric cancer cells to endothelial cells by blocking E-selectin expression.

Inhibition of TNF-α-Induced Inflammation by Andrographolide via Down-Regulation of the PI3K/Akt Signaling Pathway

Andrographolide inhibits melanoma tumor growth by inactivating the TLR4/NF-κB signaling pathway

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.

Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine.

Andrographolide Ameliorates Diabetic Retinopathy by Inhibiting Retinal Angiogenesis and Inflammation

Angelol-A exerts anti-metastatic and anti-angiogenic effects on human cervical carcinoma cells by modulating the phosphorylated-ERK/miR-29a-3p that targets the MMP2/VEGFA axis

Andrographolide suppresses the malignancy of pancreatic cancer via alleviating DNMT3B-dependent repression of tumor suppressor gene ZNF382

Andrographolide Suppresses the Growth and Metastasis of Luminal-Like Breast Cancer by Inhibiting the NF-κB/miR-21-5p/PDCD4 Signaling Pathway

ASC, a Bioactive Steroidal Saponin from Ophitopogin Japonicas, Inhibits Angiogenesis Through Interruption of Src Tyrosine Kinase‐dependent Matrix Metalloproteinase Pathway

Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response

DDA Suppresses Angiogenesis and Tumor Growth of Colorectal Cancer in Vivo Through Decreasing VEGFR2 Signaling

LYG-202 Inhibits Activation of Endothelial Cells and Angiogenesis Through CXCL12/CXCR7 Pathway in Breast Cancer

Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer

Andrographolide inhibits human hepatoma-derived Hep3B cell growth through the activation of c-Jun N-terminal kinase.

Andrographolide Inhibits Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway in Activated Macrophages